12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SAR236553: Additional Phase II data

Additional data from the double-blind, placebo-controlled, international Phase II Study 1003 trial in 77 patients with heFH showed that subcutaneous REGN727 as adjunct to lipid lowering therapy produced significant reductions in mean LDL-C from baseline to week 12 of 28.9% for the 150 mg once-monthly dose (p=0.0113); 31.54% for the 200 mg once-monthly dose (p=0.0035); 42.53% for the 300 mg once-monthly dose (p<0.0001); and 67.9% for the 150 mg...

Read the full 323 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >